Kisspeptin Administration Subcutaneously to Patients With IHH
Hypogonadotropic Hypogonadism
About this trial
This is an interventional other trial for Hypogonadotropic Hypogonadism focused on measuring Hypogonadotropic Hypogonadism, Kisspeptin, Idiopathic Hypogonadotropic Hypogonadism, GnRH
Eligibility Criteria
Inclusion Criteria: Congenital IHH o Confirmed diagnosis by medical provider supported by low sex steroids in the setting of low or inappropriately normal gonadotropins Normal blood pressure (systolic BP < 140 mm Hg, diastolic < 90 mm Hg) Not using hormonal replacement or willing to complete an appropriate washout for that particular medication and method of administration No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and method of administration Exclusion Criteria: Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol History of a medication reaction requiring emergency medical care Excessive alcohol consumption (>10 drinks/week) and/or active use of illicit drugs o Any active use of marijuana will be evaluated by a study medical professional to determine if it may impact study participation. Individuals who regularly use marijuana may be asked to washout as referenced in the medication washout section below. Pregnant or trying to become pregnant Breast feeding History of bilateral oophorectomy (ovaries were removed)
Sites / Locations
- Massachusetts General HospitalRecruiting
Arms of the Study
Arm 1
Experimental
kisspeptin pump
SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)